Allecra Therapeutics

📍 Saint Louis, France🗓 Founded 2013👥 10 employees💰 Last funded Nov 2017
Biotechnology Research🌐 allecra.com
Website LinkedIn
Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam, has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled, double-blind, global Phase 3 trial, and the Company is preparing submissions for marketing approval in the U.S. and EU based on these results. The Company has significant patent protection covering proprietary enmetazobactam in major territories. Allecra’s investors are: Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMedPartners. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Germany
1
Switzerland
1
Frequently asked questions
Who invested in Allecra Therapeutics?
Allecra Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Allecra Therapeutics last raise funding?
The most recent investment in Allecra Therapeutics recorded on gritt.io was in November 2017.
When was Allecra Therapeutics founded?
Allecra Therapeutics was founded in 2013.
What industry is Allecra Therapeutics in?
Allecra Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Allecra Therapeutics based?
Allecra Therapeutics is headquartered in Saint Louis, France.